A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2018
Price : $35 *
At a glance
- Drugs F16 IL2 fusion protein (Primary) ; Paclitaxel
- Indications Merkel cell carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms IMMOMEC
- Sponsors Philogen
- 06 Oct 2018 This trial has been discontinued in Spain.
- 30 Jan 2018 This trial has been discontinued in Denmark (End Date: 2017-12-15).
- 26 Jan 2018 This trial has been discontinued in Germany